The R-Pharm Group of Companies took part in the 11th annual conference of the Saudi Arabian Rheumatology Society. The event was attended by over 300 rheumatologists, pediatricians, and internal medicine specialists from Saudi Arabia and other countries.
At the satellite symposium, experts presented the results of studies of the R-Pharm Group of Companies’ own original drugs. Thus, Professor Maxim Korolev, Head of the Research Institute of Clinical and Experimental Lymphology, Chief Rheumatologist of the Novosibirsk Region, spoke about the results of the CREDO clinical trial program for the drug olokizumab (Artlegia), including data from the study (CREDO 4), which assessed the long-term safety and efficacy of olokizumab.
Alexander Dubikov, Head of the Department of Faculty Therapy and Propaedeutics of Internal Medicine at the Pacific State Medical University, shared his experience of using olokizumab in patients with rheumatoid arthritis and concomitant diseases.
The report by Mikhail Kostik, Professor of the Department of Hospital Pediatrics at the St. Petersburg State Pediatric Medical University, was devoted to the long-term use of the drug goflikicept (Arcerix) in patients with idiopathic recurrent pericarditis and familial Mediterranean fever.
At the end of the symposium, the President of the Saudi Arabian Rheumatology Society, Dr. Hanan Mohammad Al Rayes, thanked the R-Pharm group of companies for supporting the conference.
“It has become a good tradition for R-Pharm to participate in the conference of the Saudi Arabian Rheumatology Society. This year, a number of Russian scientists shared data from the latest clinical studies of Artlegia and Arcerix, as well as experience of use in real clinical practice, which generated significant interest from the audience, reflecting the relevance of using innovative biological drugs in the treatment of autoimmune and autoinflammatory diseases in the Persian Gulf countries,” says Mikhail Samsonov, Medical Director of the R-Pharm Group.
